


Product Name: Recombinant Human KLK2 (C-6His)
Catalog #: PHH1033



Summary

Name	Kallikrein 2/KLK2
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<0.01 EU/μg as determined by LAL test.
Construction	Recombinant Human Kallikrein 2 is produced by our Mammalian expression system and the target gene encoding Pro19-Pro261 is expressed with a 6His tag at the C-terminus.
Accession #	P20151
Host	Human Cells
Species	Human
Predicted Molecular Mass	27.9 KDa
Formulation	Supplied as a 0.2 μm filtered solution of 20mM Acetate, 250mM Trehalose, 0.02% Tween 80, pH5.0.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	

SDS-PAGE image



Background

Alternative Names	Kallikrein-2; Glandular Kallikrein-1; hGK-1; Tissue Kallikrein-2; KLK2
Background	Kallikrein-2 (KLK2) is a secreted serine protease that belongs to the peptidase S1

Product Name: Recombinant Human KLK2 (C-6His)
Catalog #: PHH1033



family of Kallikrein subfamily. KLK2 contains 1 peptidase S1 domain. It is highly expressed in the human prostate gland. KLK2 can cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, but Preferential cleavages of Arg-|-Xaa bonds in small molecule substrates. It also highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met-|-Xaa or Leu-|-Xaa. KLK2 is inhibited by serpins such as protein C inhibitor, antichymotrypsin, and plasminogen. KLK2 is considered to be a biomarker for prostate cancer.

Note

For Research Use Only , Not for Diagnostic Use.